TD Cowen analyst Brendan Smith maintained a Buy rating on Repligen today and set a price target of $200.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brendan Smith has given his Buy rating due to a combination of factors including Repligen’s impressive organic growth and strong performance across various segments. The company reported a year-over-year organic growth of 11%, with a notable 17% increase excluding COVID-related impacts, surpassing market expectations. This growth is attributed to the robust performance in chromatography, ATF, and process analytics, indicating a recovery in the bioprocessing sector.
Furthermore, Repligen’s management has proactively addressed potential challenges, such as the recent downturn in gene therapy sentiment and tariff impacts, by adjusting their fiscal guidance accordingly. The company’s strategic reinvestment in regions like China, despite a slight revenue decline, suggests a long-term growth potential. Brendan Smith believes that Repligen is well-positioned to sustain above-market growth rates, making it a compelling investment opportunity in the bioprocessing industry.
In another report released today, Craig-Hallum also maintained a Buy rating on the stock with a $0.00 price target.